Medulloblastoma non-WNT/non-SSH

This subgroup includes all other cases of medulloblastoma that do not have the genetic alterations associated with WNT or SHH subtypes. It is a heterogeneous group, meaning it includes various genetic and molecular subtypes that do not fit into the WNT or SHH categories.

Non-WNT/non-SHH medulloblastoma is typically associated with an intermediate prognosis, meaning the outcome can vary from patient to patient. Treatment strategies for this subgroup may depend on the specific genetic characteristics of the tumor and the individual patient's risk factors.

It's important to note that ongoing research in molecular biology and genetics is leading to a deeper understanding of medulloblastoma subgroups, which can help guide treatment decisions and improve outcomes for patients with this type of brain tumor.

Group 3 medulloblastoma

Group 4 medulloblastoma.

Results suggest that the specific molecular subtypes of Group 3/4 medulloblastoma could serve as valuable markers for predicting outcomes, especially for patients receiving lower-dose craniospinal irradiation treatment. This information might help tailor treatments more effectively for individual patients, potentially reducing the intensity of treatment for some while maintaining positive outcomes ¹⁾.

¹⁾

Fukuoka K, Kurihara J, Shofuda T, Kagawa N, Yamasaki K, Ando R, Ishida J, Kanamori M, Kawamura A, Park YS, Kiyotani C, Akai T, Keino D, Miyairi Y, Sasaki A, Hirato J, Inoue T, Nakazawa A, Koh K, Nishikawa R, Date I, Nagane M, Ichimura K, Kanemura Y. Subtyping of Group 3/4 medulloblastoma as a potential prognostic biomarker among patients treated with reduced dose of craniospinal irradiation: a Japanese Pediatric Molecular Neuro-Oncology Group study. Acta Neuropathol Commun. 2023 Sep 25;11(1):153. doi: 10.1186/s40478-023-01652-4. PMID: 37749662.